Dementia and Alzheimer Disease

SCI-110 not only met its primary safety end points, but the agent showed benefits on secondary outcomes such as need to use rescue medication and exploratory outcomes such as appetite.

Acting as an advocate is meaningful to neurologists because it speaks to their inner core—or their “why.” Neurologists have the agency to make this world a better place while working as a neurologist and an advocate at many levels.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is headache and migraine.

Neurology News Network for the week ending November 5, 2022. [WATCH TIME: 3 minutes]

The brain monitoring platform can be used in a number of settings, including the ICU and doctor’s offices, to monitor and detect cognitive decline related to neurodegenerative disease, as well as screening in clinical trials.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 4, 2022.

Patients treated with PC-rTMS showed almost no decline in the CDR-SB score, and presented a clear advantage in terms of cognitive functions in contrast to the worsening of the score observed in the sham group.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is epilepsy and seizure disorders.

Neurology News Network for the week ending October 28, 2022. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 28, 2022.

Foralumab, an anti-CD3 monoclonal antibody, has been previously assessed in diseases such as progressive multiple sclerosis and Crohn disease, as well as in patients with mild to moderate COVID-19.

Here's some of what is coming soon to NeurologyLive® this week.

Changes in plasma pTau217 and GFAP levels from donanemab significantly correlated with percent change in amyloid plaque level as measured by amyloid PET imaging.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the European Committee for Treatment and Research in Multiple Sclerosis.

The composite score, which consisted of 6 linguistic features and 3 acoustic features, was shown to be sensitive to measures of disease progression, with a potential to help understand treatment response.

Neurology News Network for the week ending October 22, 2022. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 21, 2022.

The director of the Center for Brain Health and Alzheimer prevention clinic at FAU medicine shares his experience during the Medical Crossfire session on the Alheimer pipeline that he took part in at the fourth annual International Congress on the Future of Neurology. [WATCH TIME: 7 minutes]

Mind Moments®, a podcast from NeurologyLive®, brings you exclusive interviews with Stephen Krieger, MD; Richard Isaacson, MD; and Jessica Ailani, MD. [LISTEN TIME: 24 minutes]

The director of the Center for Brain Health and Alzheimer prevention clinic at FAU medicine provides commentary about his time at the fourth annual International Congress on the Future of Neurology. [WATCH TIME: 4 minutes]

The director of NYU Langone’s Alzheimer’s Disease Research Center discussed noticeable advancements within the field of Alzheimer disease in recent years and how they contribute to gaining a better understanding of the disease. [WATCH TIME: 5 minutes]

The director of the Center for Brain Health and Alzheimer prevention clinic at FAU medicine shares his experience at the fourth annual International Congress on the Future of Neurology. [WATCH TIME: 3 minutes]

In a phase 2 study, fosgonimeton showed positive effects on measures of cognition, function, and neurodegeneration when taken as a monotherapy, prompting an unblinded interim analysis.